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Abstract
Background: Skeletal muscle is a major regulator of systemic metabolism as it serves as the major site for glucose
disposal and the main reservoir for amino acids. With aging, cachexia, starvation, and myositis, there is a preferential
loss of fast glycolytic muscle fibers. We previously reported a mouse model in which a constitutively-active Akt
transgene is induced to express in a subset of muscle groups leading to the hypertrophy of type IIb myofibers
with an accompanying increase in strength. This muscle growth protects mice in various cardio-metabolic disease
models, but little is known about the underlying cellular and molecular mechanisms by which fast-twitch muscle
impacts disease processes and regulates distant tissues. In the present study, poly (A) + tail mRNA-seq and non-
targeted metabolomics were performed to characterize the transcriptome and metabolome of the hypertrophic
gastrocnemius muscle from Akt1-transgenic mice.
Results: Combined metabolomics and transcriptomic analyses revealed that Akt1-induced muscle growth mediated
a metabolic shift involving reductions in glycolysis and oxidative phosphorylation, but enhanced pentose phosphate
pathway activation and increased branch chain amino acid accumulation. Pathway analysis for the 4,027 differentially
expressed genes in muscle identified enriched signaling pathways involving growth, cell cycle regulation, and
inflammation. Consistent with a regenerative transcriptional signature, the transgenic muscle tissue was found to be
comprised of fibers with centralized nuclei that are positive for embryonic myosin heavy chain. Immunohistochemical
analysis also revealed the presence of inflammatory cells associated with the regenerating fibers. Signal peptide
prediction analysis revealed 240 differentially expressed in muscle transcripts that potentially encode secreted proteins.
A number of these secreted factors have signaling properties that are consistent with the myogenic, metabolic and
cardiovascular-protective properties that have previously been associated with type IIb muscle growth.
Conclusions: This study provides the first extensive transcriptomic sequencing/metabolomics analysis for a model of
fast-twitch myofiber growth. These data reveal that enhanced Akt signaling promotes the activation of pathways that
are important for the production of proteins and nucleic acids. Numerous transcripts potentially encoding muscle
secreted proteins were identified, indicating the importance of fast-twitch muscle in inter-tissue communication.
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Background
The ability of skeletal muscle to quickly adapt its structure
and function to external stimuli allows for diverse move-
ment, and this is associated with systemic metabolic and
cardiovascular changes to meet the changing functional
demands of the muscle. The mass and composition of
skeletal muscle is broadly determined by regulatory
systems that control the balance between muscle protein
synthesis and degradation [1]. Skeletal muscle serves as
the major protein and glycogen reservoir and the prime
site for insulin-induced glucose disposal. In response to
aging, inactivity, cancer or other advanced diseases, skel-
etal muscle mass is reduced, presumably to provide energy
for physiological recovery. However, the net breakdown of
muscle and the consequent loss of strength under such
conditions can lead to metabolic dysfunction, and con-
tribute to morbidity [2] and mortality [3].
Skeletal muscle is comprised of multiple fiber-type com-
ponents that vary in their contractile properties, metabolic
capacities and innervation by motor neurons. Based on
myosin heavy chain (MyHC) isoform expression, adult
mammalian myofibers can be subdivided into four major
types: a slow, oxidative fiber expressing MyHC I and three
fast glycolytic fibers expressing MyHC IIa, IIx, and IIb (in
mouse). In humans, however, only type I, IIa and IIx
myofibers are present [4]. There are also hybrid myofibers
expressing mixed MyHC isoforms with intermediate char-
acteristics (for example, MyHC IIa/IIx). Different myofiber
types exhibit distinct transcriptional profiles. For example,
transcripts enriched in the MyHC I fibers are primarily
associated with ribosomal and contractile proteins, and
enzymes involved in oxidative phosphorylation and fatty
acid metabolism [5]. In contrast, genes expressed in
MyHC IIb fibers tend to be more functionally diverse, but
groups are associated with glycolysis/gluconeogenesis and
insulin signaling [5]. Selective recruitment of different
populations of fibers offers a wide range of performance
capabilities from long lasting, low mechanical outputs
with minimal fatigue (by slow, oxidative myofibers) to
high-power, short-duration contractions (by fast, glycolytic
myofibers). The fiber composition of a muscle is deter-
mined partly by genetic factors and is capable of changing
in response to functional demands and stimuli. For ex-
ample, resistance exercise induces functional and tran-
scriptional changes targeted to the fast glycolytic fibers
[6]. Moreover, myofiber type diversity affects the suscepti-
bility of different muscles to muscle wasting state and dis-
ease. During aging, a preferential loss and atrophy of
glycolytic, type II fiber is observed in both human and
mice. Selective atrophy of type II [7] myofibers has also
been reported in patients with steroid-induced myopathies
[8], peripheral arterial disease [9], denervation [10], cancer
cachexia [3], and respiratory failure [11]. Furthermore,
several types of muscular dystrophy, such as Duchenne
muscular dystrophy [12], and autoimmune diseases, such
as myasthenia gravis [10], have been shown to induce
muscle atrophy specifically in type II myofibers. Con-
versely, an association occurs between the loss of oxidative
myofiber metabolism and insulin resistance [13]. However,
recent studies in experimental systems have raised the
possibility that the myofiber shift from oxidative to glyco-
lytic metabolism may serve as an adaptive response to the
diabetic state [14].
In contrast to the large number of molecular studies
on oxidative fibers, there is a paucity of information on
the roles that fast-twitch muscle fibers play in muscle
diseases and metabolic function. To address this issue,
we developed a conditional mouse model, dubbed the
“MyoMouse”, that inducibly expresses a constitutively
activated form of Akt1 specifically in skeletal muscle
[15]. Akt1 is a serine/threonine kinase that regulates
cell survival, growth, and metabolism in variety of tis-
sues and cell types. In skeletal muscle, the Akt signaling
pathway is activated during myogenic differentiation
[16], by anabolic stimuli including growth factors (i.e.,
insulin and Igf1) [17], and by resistance exercise and
nutritional inputs [18]. Induction of Akt1 signaling
pathway leads to an increase in myofiber hypertrophy
[17], whereas inactivation of Akt signaling leads to
Foxo mediated muscle atrophy [19]. In the MyoMouse
model, Akt1 transgene activation promotes the selective
hypertrophy of type IIb muscle fibers in a rapamycin-
dependent manner in a subset of muscle groups [15].
Mice expressing the muscle-specific transgene display an
increase in strength, but not an increase in running per-
formance. Transgene activation in the MyoMouse model
leads to a modest 5% increase in lean muscle mass, a
physiologically relevant level that is on par with the
muscle mass loss that occurs in the early stages of aging
or disease [20].
A series of studies have used the MyoMouse model to
examine the consequences of Akt1-mediated muscle
growth in various models of chronic disease and acute in-
jury. A relatively modest increase in myofiber growth in
obese mice leads to marked reductions in fat mass and
body weight, resolution of hepatic steatosis, and improve-
ments in systemic metabolic parameters [15]. Notably,
these metabolic improvements were associated with in-
creased fatty acid oxidation in a remote tissue (i.e. liver),
but not in muscle. Consistently, the restoration of muscle
mass by Akt1-gene activation can correct age-associated
impairments in systemic metabolism in mice fed a stand-
ard chow [20]. Other studies have shown that this model
of muscle growth can have protective effects on distant or-
gans in acute injury models of disease that are associated
with the loss of skeletal muscle mass. Akt1-mediated
muscle growth has been shown to protect against renal
failure in two models of kidney injury [21], and diminish
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adverse cardiac remodeling following left anterior cor-
onary artery ligation [22]. The MyoMouse model has
also been employed to document the protective actions
of acute Akt1 transgene activation in muscle per se.
Myogenic Akt signaling promotes sarcolemma stability
and attenuates muscle degeneration in a model of
Duchenne muscular dystrophy and improves regener-
ation in a cardiotoxin injury model [23, 24].
The striking changes observed in muscle and remote
tissues of the MyoMouse have led us to speculate about
the roles of “myokines”, i.e. hormonal factors released
by muscle that confer some of the beneficial actions of
exercise training [25, 26]. A number of strategies have
been employed to isolate and characterize the muscle
secretome involving, for example, comparisons of
sedentary and exercised muscles [27], muscle growth
following endurance training [28], muscle electrical
stimulation [29], or development of lipid-induced insu-
lin resistance [30], etc., and a number of myokine
candidates have been identified. To date, a systematic
analysis of the muscle secretome of the MyoMouse has
not been performed, although this model exhibits a
number of features that may provide unique insights.
As discussed above, it is a model of selective fast-twitch
fiber growth in mouse, and these are the myofibers that
are preferentially lost in aging, sarcopenia and cachectic
conditions. The effects of glycolytic muscle growth in
this model are independent of exercise, nutritional in-
put or surgical intervention, that can have confounding
effects on the secretome. Finally, the effects of glyco-
lytic muscle growth in the MyoMouse model is robust
and rapid, potentially leading to an amplification in the
levels of molecules involved in these regulatory events.
Thus, to better characterize the cellular and molecular
mechanisms involved in fast-twitch muscle growth, and
its impact on the muscle secretome, we performed an
in-depth and combined analysis of the transcriptome
and metabolome on the growing muscles from the
muscle-specific Akt1 transgenic mice.
Methods
Animals
Skeletal muscle-specific conditional Akt1 transgenic
mice (DTG) were generated by mating of 1256 [3Emut]
Mck-rtTA [31] and Tre-myrAkt1 [32] transgenic mice
as previously described [15]. All mice were genotyped
by PCR from tail DNA. Mice were provided with chow
and water ad libitum and housed in pairs on a fixed 12-
h light/dark cycle in the Laboratory Animal Science
Center at Boston University School of Medicine. At the
age of 4 months, male DTG mice were treated with
0.5 mg/ml doxycycline (AB03550, American Bioanalyti-
cal) in drinking water for 2 weeks to induce skeletal
muscle-specific Akt1 overexpression. To eliminate the
effect of doxycycline water on muscle metabolism, Mck-
rtTA or Tre-myrAkt1 single transgenic littermates, used
as controls, were treated with doxycycline in the same
manner as DTG mice. A day before, tissue harvest,
body composition was assessed by non-invasive quanti-
tative magnetic resonance (EchoMRI700, EchoMRI
LLC, Houston, TX) at BUMC Metabolic Phenotyping
Core. Mice were starved overnight before the day of sacri-
fice. Bilateral gastrocnemius muscles collected from anes-
thetized DTG and Mck-rtTA mice were weighed, snapped
frozen in liquid nitrogen, and stored at−80 °C until
analysis. All experiments were performed in adherence
with NIH guidelines on the Use of Laboratory Animals,
and were approved by the Institutional Animal Care and
Use Committee at Boston University.
RNA extraction and sequencing
Total RNA was isolated using TRIzol Reagent (Life
Technologies, Grand Island, NY) according to manufac-
turer’s instructions followed by DNase I treatment using
Qiagen (Valencia, CA) RNeasy Mini columns. The ex-
tracted RNA samples were analyzed using a BioAnalyzer
and only high quality RNA samples (RIN > 8.5) were sent
to Expression Analysis, Inc. (Durham, NC) for library
preparation and sequencing (n = 4 per group). The mRNA
library was prepared by Illumina TrueSeq stranded mRNA
sample. Eight library preparations were loaded on two
lanes of the Illumina HiSeq 2500 machines (Illumina, San
Diego, CA) for paired-end 50 bp sequencing using the
standard Illumina mRNA-seq protocol.
RNA-seq data analyses
To prepare sequence reads for alignment, sequence adap-
tors were removed from sequences using Fastq-Mcf
(code.google.com/p/ea-utils/wiki/FastqMcf). Several qual-
ity control steps were taken to assure quality, including
the Illumina spike-in controls for each step of library prep,
Life Technologies ERCC RNA spike-in control mix1 at
the beginning of library prep, and UHRR control speci-
men for each plate batch of RNA-seq. Sequence reads
with high-quality score (Phred score) of 33 and above
were mapped to mm10 transcriptome using RNA-seq by
Expectation Maximization (RSEM) v1.1.13 program [33].
After removal of the spike-in controls, an average of
59,760,883 reads were sequenced for each library prepar-
ation. There were ~88.1% sequence reads aligned to the
transcriptome. At the gene level, aligned reads were anno-
tated to 18,077 genes out of 30,743 genes defined by
mm10 (58.8%). Genes with sequence reads less than 3 in
at least 6 samples were considered as not detectable and
thus filtered out from further analysis. All 8 samples were
normalized by upper quartile normalization. Differential
expression analysis was performed using edge-R where
Fisher’s exact test was utilized. Genes or isoforms with
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false discovery rate (FDR) ≤ 0.005 and fold change ≥ 2
were considered as significantly differentially expressed
genes (DEG) between two groups. The RNA sequencing
data are available for download from the NCBI Gene
Expression Omnibus database (GEO: GSE85763).
Metabolomics
Unbiased metabolite profiling was performed using ion-
pairing liquid chromatography/tandem mass spectrometry
(Ion Pair LC/MS/MS) and gas chromatography tandem
mass spectrometry (GC/MS/MS). Gastrocnemius was ho-
mogenized in methanol (100 mg/mL) by a ball-mill
(MM301, Retsch GmbH, Haan, Germany), and centri-
fuged at 15,000 rpm for 5 min. 100 μL supernatant was
mixed with sample buffer (5% octylamine, 3.5% acetic acid
in 50% methanol), and centrifuged at 15,000 rpm for
5 min. The supernatant was transferred to a sample vial
and placed in an autosampler (4 °C). For LC/MS analysis,
each 10 μL sample was injected onto a reverse phase
column from Atlantis T3 (2.1 × 100 mm, 3 μm, 130 Å,
Waters co., Milford, MA, USA) and maintained at 35 °C.
Subsequently, chromatographic separation was performed
by gradient elution of mobile phase A, 0.1% octylamine,
0.07% acetic acid and 10 μM EDTA-2Na in MilliQ water,
and mobile phase B, 0.07% acetic acid in methanol/isopro-
panol (4:1). The gradient started at 1% B for 2 min, in-
creased up to 100% B in 10.5 min, maintained at 100%B
for 4.5 min, then decreased to 1% B, and kept at 1% B for
10 min. Mass spectrometry analysis was performed using
a QTRAP5500 mass spectrometer (AB Sciex Pte. Ltd.,
Toronto, Canada). The elution from liquid chromatog-
raphy was directly introduced to electrospray ionization
by using a Turbo spray ionization probe (AB Sciex Pte.
Ltd., Toronto, Canada) with vaporizer temperature set at
475 °C. Multiple Reaction Monitoring (MRM) was used to
detect the targeted molecules; where 148 molecules were
detected by positive ionization and 188 molecules by
negative ionization mode using simultaneous polarity
switching. MRM conditions were set using reference
conditions in the report by Yuan M et al. [34], with
partially optimized standard reagents. LC/MS/MS data
were processed by MultiQuant 3.0 (AB Sciex Pte. Ltd.,
Toronto, Canada), and the peak areas were exported
to spread sheet and analyzed by Excel. For GC/MS/
MS analysis, 50 μL of the homogenized supernatant
were dried by nitrogen stream, and then derived by
two-step reactions: oximation and trimethylsilylation.
Oximation reaction was performed by adding 25 μL of
O-methylhydroxylammonium chloride in pyrimidine
(15 mg/mL), and incubated at 40 °C for 60 min. Subse-
quently, for trimethylsilylation reaction, 25 μL of N,
O-bis (trimethylsilyl) trifluoroacetamide (BSTFA) with
1% trimethylchlorosilane (TMCS) was added to the re-
action solution, and incubated at 60 °C for 60 min.
The reaction mixture, 1 μL, was injected into an Agilent
7890A series gas chromatography system by split injection
mode (10/1, v/v) using a GC injector 80 autosampler
(Agilent Technologies Inc.). Gas chromatography separ-
ation was performed in a J&W Scientific DB-5MS-DG
column (30 m × 0.25 mm i.d., df = 0.25 μm, Agilent
Technologies Inc.) by temperature gradient, which rises
at 10 °C/min from 60 °C to 325 °C, with consistent he-
lium gas flow at 1 mL/min. The elution was ionized by
electron impact ionization (70 eV) with an ion source
temperature at 280 °C, and introduced to an Agilent
7010B triple-quadrupole mass spectrometer. Each tar-
get molecule was detected by MRM and the corre-
sponding peak area was exported to an Excel spread
sheet for further analysis. Differential expression ana-
lysis of the metabolites between the two groups were
performed by Student’s T-test. Metabolites with p-value
< 0.1 and fold change ≥ 1.5 or ≤ -1.5 were considered as
statistically significant different.
Pathway and functional analysis
Integrative pathway analysis for both differentially
expressed genes and metabolites were performed using
MetaboAnalyst 3.0 (www.metaboanalyst.ca) using default
settings. Canonical signaling pathway and upstream
regulator analysis were performed by uploading DEGs
on to the Ingenuity Pathway Analysis package and ana-
lyzed using default settings (Qiagen, CA, USA).
Secreted protein prediction and protein class annotation
To identify putative secreted proteins in Akt1-mediated
muscle growth, five independent databases were queried.
First, sequences of differentially expressed isoforms identi-
fied from RNA-seq analysis (FDR < 0.005 and fold
change ≥ 1.5 or ≤ -1.5) were downloaded from UCSC Gen-
ome website (https://genome.ucsc.edu/cgi-bin/hgTables).
Second, downloaded sequences were submitted to Signal
P 3.1 Server (http://www.cbs.dtu.dk/services/SignalP/) to
predict the presence of eukaryotic signal peptide at the
N-terminus of protein using default settings. Third, se-
quences predicted to be absent of classical signal
peptide were submitted to Secretome P 2.1 server
(http://www.cbs.dtu.dk/services/SecretomeP/) to predict
for the presence of non-classical signal peptide. Fourth, se-
quences positive for either classical or non-classical signal
peptide were submitted to TMHMM server (http://
www.cbs.dtu.dk/services/TMHMM/) to screen for trans-
membrane helices in protein sequence. Subsequently, se-
quences positive for either classical or non-classical
secreted proteins but lack of transmembrane helices were
submitted to WoLF PSORT database for a final screen
for protein localization [35]. After removing sequences
predicted to be predominantly located at places other
than extracellular matrix (e.g. nucleus, mitochondria,
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endoplasmic reticulum, lysosome, and membrane, etc.)
by WoLF PSORT, the remaining sequences are consid-
ered as a putative secreted protein, and thus a potential
myokine. The list of DEG was uploaded to Panther
Classification System for statistical overrepresentation
test using PANTHER Protein Class annotation data set
(http://www.pantherdb.org/). The heat map was gener-
ated by using GENE-E software from Broad Institute
(Cambridge, MA).
Immunohistochemistry
Medial and lateral gastrocnemius muscles were dissected,
mounted separately on a wooden tongue depressor using
OCT, immediately snap freeze in pre-chilled isopentane
by liquid nitrogen, and stored at -80 °C. The frozen
muscles were serially sectioned at 10 μM from the muscle
mid-belly and mounted on microscope slides. For myofi-
ber typing, unfixed sections were incubated at RT for
30 min, blocked by 10% BSA in PBST for 1 h, and incu-
bated overnight at 4 °C with antibodies against MyHC
isoform type I (BA.D5 mouse IgG2b), type IIA (SC.71
IgG1), type IIx (6H1 mouse IgG) from DSHB at 1:200
dilution. The next day, slides were washed and incubated
with immunoglobulin-specific secondary antibodies at
1:200 dilution at room temperature (RT) for 1 h: Goat
anti-mouse IgG2b AF350 (A21140), Goat anti-mouse
IgG1 AF488, Goat anti-mouse IgM AF647 (A21238) from
Invitrogen (Carlsbad, CA). Slides were post-fixed in ice-
cold methanol for 10 min. After wash, sections were incu-
bated with rabbit anti-mouse laminin antibody (L9393;
Sigma) at 1:200 dilution in 1% BSA for 2 h at RT, followed
by 1 h incubation in Texas-Red-X goat anti-rabbit IgG at
1:200 dilution (T-6491; Invitrogen) at RT. Sections were
mounted on a coverslip with Vectashield mounting
medium (H1000; Vector Lab, Burlingame, CA). For em-
bryonic MyHC staining, sections were first fixed in 4%
paraformaldehyde in PBS for 10 min and blocked with
MOM Ig blocking reagent for 5 min (MKB-2213; Vector
Lab). After washing, sections were incubated overnight in
eMHC antibody from DSHB (F1.652 IgG2) at 1:1000
dilution, washed and incubated with Goat anti-mouse
IgG2 AF488 at 1:200 dilution for 1 h. Sections were
then stained for laminin as previously described and
mounted in Vectashield mounting medium with DAPI
(H1200) for imaging. For CD68 and F/480 staining, sections
were first fixed and blocked as described above embryonic
MyHC staining protocol. Sections were then incubated
with Rat anti-mouse CD68 IgG2a or F4/80 IgG2b (at 1:100
dilution) with anti-laminin antibody (at 1:250 dilution)
overnight at 4 °C. The next day, slides were washed, incu-
bated with 1:250 dilutions of donkey anti-rat AF 594 and
goat anti-rabbit IgG AF488 for 1 hour, and mounted in
Vectashield mounting medium with DAPI for imaging. Im-
ages were captured with a BZ-9000 Keyence microscope
camera at 20× magnification (Elmwood Park, NJ). Fiber
cross-sectional area was circled manually and calculated by
Keyence microscope. The average number of fibers mea-
sured for each myofiber type per muscle was 200.
Statistical analyses
Statistical analyses of the RNA-seq and metabolomics
data have been described above. All other statistical ana-
lysis was performed using GraphPad Prism 5.0 software
(La Jolla, CA). For muscle weight, total RNA content
and qPCR experiments, non-parametric Mann–Whitney
test was used to determine whether there is a significant
difference between the 2 groups. P < 0.05 is considered
significantly different.
Results
Characterization of muscle growth induced by Akt1
transgene activation
To analyze the hypertrophy of skeletal muscle due to
Akt1 overexpression, gastrocnemius muscles were col-
lected from mice that were positive for both Mck-rtTA
and TRE-Akt1 transgene (i.e. double-transgenic (DTG)
mice,) and Mck-rtTA single transgenic (MckrtTA) mice
(also referred to as STG mice). Consistent with prior
findings [15], 2 weeks of doxycycline treatment led to a
significant induction in Akt1 phosphorylation in gastro-
cnemius muscles from DTG mice compared to control
(Additional file 1: Figure S1A). This was associated with
significant muscle growth and myofiber hypertrophy in
DTG mice (Fig. 1a-c), and an 1.3-fold increase in gastro-
cnemius muscle weight (Fig. 1d). Because transgene acti-
vation only occurs in a small subset of muscle groups,
there was no increase in muscle mass for tibialis anterior
(TA), soleus (SOL) or extensor digitalis longus (EDL,
Fig. 1d), that do not express the transgene, and no statisti-
cally significant change in body weight or body compos-
ition under these experimental conditions (Additional
file 1: Figure S1B, C).
To better understand the consequences of acute Akt
activation, an in-depth immunohistochemical staining
analysis with various myosin heavy chain (MHC) anti-
bodies was performed on gastrocnemius muscle sections.
With regard to fiber cross-sectional area, there was a sig-
nificant 9.5% increase in type IIb myofibers in the DTG
versus control mice (Fig. 1e). Conversely, there were 38%
and 24.3% reductions in type I and type IIa fibers, respect-
ively. With regard to myofiber type frequency, Akt1-medi-
ated gastrocnemius muscle growth led to a 27% increase
in percentage of type IIb myofibers in DTG mice (Fig. 1f).
These results confirm and extend our prior analysis of this
model [15], and they define the degree of muscle growth
following Akt1-transgene activation under the conditions
employed for transcriptomic and metabolomic analyses
employed in this study.
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Identification of differentially expressed genes (DEG) in
hypertrophied muscle
To understand the transcriptome changes associated with
Akt1-mediated muscle growth, next-generation polyA (+)
RNA sequencing was performed on the gastrocnemius
muscle of DTG mice and their littermate MckrtTA con-
trol mice. We chose to study muscle growth at the 2-week
time point because the muscle hypertrophy is at the be-
ginning of log phase increase measured by muscle weight
(Additional file 1: Figure S1d). Using statistical cutoff of
FDR < 0.005 and fold change ≥2 or ≤−2, we identified
4,027 genes that were differentially expressed between
Akt1 transgenic muscle compared to control muscle.
Among these, 2,009 genes were upregulated and 2,218
were downregulated (Additional file 2: Table S1). These
DEG are displayed in the heat map in Fig. 2a (left panel)
to illustrate the degree of reproducibility between mice.
Metabolic pathways affected by the Akt1-mediated
muscle growth
To understand the metabolome changes associated with
Akt1-mediated muscle growth, untargeted metabolome
was performed in gastrocnemius muscles using LC/MS/
MS and GC/MS/MS platform. Among the 139 metabo-
lites that could be detected, 29 were upregulated and 24
were downregulated using a statistical cutoff of p-value
< 0.1, fold change ≥ 1.5 or ≤ -1.5 (Fig. 2a right panel,
Additional file 3: Table S2). The combined transcrip-
tomic and metabolomic data were analyzed using the
MetaboAnalyst 3.0 data analysis tool [15] to identify the
metabolic pathways that are enriched by Akt1-mediated
muscle growth. Using this tool, metabolites and tran-
scripts encoding for enzymes in the pathways associated
with “glycolysis/gluconeogenesis”, “tricarboxylic acid
(TCA) cycle”, “branched chain amino acid (BCAA) deg-
radation”, and “pentose phosphate pathway”, among
others, were significantly enriched in the muscle of DTG
mice (Fig. 2b).
Akt-mediated muscle growth was accompanied by
reductions in the levels of many glycolytic pathway
intermediates including glucose-6-phosphate (G6P),
fructose-6-phosphate (F6P), fructose-1,6-bisphosphate
(FBP), 3-phosphoglycerate (3PG), and phosphoenolpyr-
uvate (PEP) (Fig. 3a). Correspondingly, transcripts encod-
ing several enzymatic steps in the glycolysis pathway were
downregulated, including aldolase A (Aldoa), triose phos-
phate isomerase 1 (Tpi1), glyceraldehyde-3-phosphate
dehydrogenase (Gapdh), and phosphoglycerate mutase 2
(Pgam2) (Fig. 3a). In a number of cases, the downregula-
tion of the transcript encoding the muscle isoform was
accompanied by the corresponding upregulation of non-
muscle isoforms. For example, a trend of downregulation





Fig. 1 Two-weeks of Akt1 transgene activation induces pronounced type IIb muscle growth in double transgenic (DTG) mice. a Skinned hind
limbs of a 24-week-old MckrtTA and DTG mice after 2 weeks of doxycycline treatment to activate myr Akt1 transgene expression. b A significant
increase in the mass of gastrocnemius muscle was found in DTG mice at 2 weeks after transgene induction compared to MckrtTA mice. c Cross-section
of the indicated gastrocnemius muscles stained with laminin (red). d Akt1-induction in DTG mice selectively increased the mass of gastrocnemius (GSN)
muscle. e Average cross-sectional area of each myofiber type from DTG mice and their littermate controls (STG) with 2 weeks of doxycycline water. There
were significant increases in CSA of type IIb fast-twitch myofibers but reduced CSA of type I and type IIa myofibers in DTG mice compared to STG
controls. f Gastrocnemius muscles from DTG showed increased percentage of type IIb myofibers compared to that from STG mice. ***p < 0.001, *p< 0.05
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of the muscle isoform Pfkm (FDR = 0.00539) was accom-
panied by the significant upregulation of the platelet (Pfkp)
isoform. Similarly, the downregulated muscle-specific
Pgam2 was accompanied by the upregulation of Pgam1.
Transcripts encoding the non-muscle isoforms were
expressed at much lower levels relative to the muscle-
specific transcripts, both in the control and transgenic
muscle conditions.
Transcriptomic data indicated a strong decrease in
mitochondrial tricarboxylic acid (TCA) cycle activity during
Akt1-mediated muscle growth (Fig. 3b). Many transcripts
encoding for enzymes in the TCA cycle were significantly
downregulated including citrate synthase (Cs), aconitase 2
(Aco2), isocitrate dehydrogenase subunits (Idh3a, Idh3b,
Idh3g), oxoglutarate dehydrogenase (Ogdh), succinate-
coenzyme A ligase (Sucla2, Suclg1, and Suclg2), fumarate
hydratase 1 (Fh1), and malate dehydrogenase 2 (Mdh2).
Although few changes were detected in the TCA cycle
metabolites, a 1.7-fold downregulation of α-ketoglutarate
(α-KG) was observed.
Consistent with reductions in transcripts encoding
TCA cycle enzymes, many genes encoding proteins re-
quired for oxidative phosphorylation were downregu-
lated during Akt1-mediated muscle growth. Expression
levels of 56 genes in the oxidative phosphorylation path-
way, specifically those encoding for key enzymes in the
electron transport chain, were downregulated more than
2-fold (Additional file 4: Figure S2 and Additional file 5:
Table S3), including those encoding for alpha or beta
subunits of NADH dehydrogenase (Ndufa1, 2, 4, 5, 6,
etc., or Ndufb2, 4, 6, 7, 8, 11), succinate dehydrogenase
(Sdha, Sdhb, Sdhc), ubiquinol-cytochrome c reductase
(Uqcrc1, Uqcrc2, Uqcr10, Uqcr11), cytochrome c oxidase
(Cox4l1, Cox4l2, Cox5a, etc.), ATP synthase (Atp5a1,
Atp5b, Atp5c1, etc.). Moreover, Akt1-mediated muscle
growth also induced a significant downregulated expres-
sion in the transcripts encoding for mitochondrial fusion
proteins (Mfn1, Mfn2, Opa1), mitochondrial permeability
transition pore proteins (Slc25a4, Vdac3) and enzymes
involved in reactive oxidative species detoxification
(Cat, Sod2).
Akt1-mediated effects on intermediate biosynthesis and
degradation pathways
In contrast to these changes in the glycolytic and TCA
pathways, there was an upregulation in the pentose
phosphate pathway that functions in the production of
intermediates for the biosynthesis of nucleotides and
amino acids (Fig. 4a). Specifically, the transcript encod-
ing glucose-6-phosphate dehydrogenase (G6pdx), the
rate limiting enzyme in this pathway, increased 3.5-fold
and phosphogluconate dehydrogenase (Pgd) increased 2.3-
fold in the DTG muscle. Consistent with an increase in
metabolite flux through the pentose phosphate pathway, a
a
b
Fig. 2 Data from poly (A+) RNA sequencing and metabolomics analyses of gastrocnemius muscle. a Heat map of transcriptional (left panel) and
metabolite (right panel) changes of Akt1-mediated muscle growth. b Integrative pathway analysis of metabolomic and transcriptomic data for Akt1
induced muscle growth. Enriched metabolic pathways represented by both differentially expressed genes and metabolites are listed on the left
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a b
Fig. 3 Schematic representations of the metabolite and transcript regulation in glycolysis and tricarboxylic acid cycle pathways. Regulated
steps in glycolysis (a) and the TCA pathways (b) in response to Akt1-mediated muscle growth are shown. Metabolites with significant
changes (from metabolome results) are shown as vertical bar graphs, whereas gene expression changes for enzymes (from RNA-seq results) are
shown as horizontal bar graphs. Open column is control (MckrtTA) and filled column is DTG mice. * denotes p-value (for metabolites) or FDR
(for transcripts) <0.005, # denotes p-value <0.05), and + denotes p < 0.1
a b
Fig. 4 Regulation of pentose phosphate pathway metabolites and transcripts upon Akt1-mediated skeletal muscle growth. a Pathway regulation is
indicated as described in the legend of Fig. 3. b Corresponding to an increase in pentose phosphate pathway flux, there was a significant 2-fold
increase in total RNA yield per mg of muscle in Akt-mediated muscle growth (p < 0.05)
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metabolite level crossover was detected by reductions
in 6-phosphogluconic acid (6PG) and G6P and a 1.8-
fold accumulation of ribose-5-phosphate (R5P). In-
creased flux through the pathway was also indicated
by increases in purines and pyrimidine metabolites
including AICAR and xanthosine (Additional file 6:
Figure S3). Also consistent with the increase in the
biosynthetic flux through this pathway, there was a
marked increase in muscle tissue total RNA (Fig. 4b).
Two weeks of Akt1 transgene activation led to an
~2.8-fold increase in total RNA in gastrocnemius
muscle (0.33 ± 0.03 μg/mg in MckrtTA vs. 0.92 ± 0.14
in DTG, p = 0.0286). The increase in tissue RNA was
probably reflective of an increase in rRNA to meet the
demand for increased protein synthesis.
BCAA pathways were also enriched in the growing
muscle. Accumulations of Ile and Leu (1.67- and 1.55-
fold, respectively) were observed during Akt1-mediated
muscle growth (Fig. 5a). Correspondingly, 17 genes en-
coding for enzymatic activities involved in the catalytic
disposal of BCAA were downregulated (Fig. 5b), includ-
ing the first 2 enzymes common to the degradation of
three amino acids, branched-chain aminotransferase
(encoded by Bcat2) and the rate limiting branched-
chain α-keto acid dehydrogenase complex (encoded by
Bckdha and Bckdhb). The primary BCAA aminotransfer-
ase isoenzyme responsible for initiating BCAA catabolism,
mitochondrial Bcat2, that is predominantly expressed by
muscle, was downregulated 2.9-fold at mRNA level. In
contrast, the much less abundant cytosolic BCAT isoen-
zyme (Bcat1), which has roles other than BCAA oxida-
tion, increased by 16.6-fold. In addition to the
accumulation of BCAA, cysteine level increased 3.79-fold
during Akt1-mediated muscle growth (p < 0.05), and in-
creased Asp level was also observed (Fig. 5a).
Signaling pathways involved in Akt1 mediated muscle
growth
To identify the canonical signaling pathways mediating
muscle growth, we performed Ingenuity Pathway Analysis
(IPA) enrichment tests for the differentially expressed
genes (Additional file 7: Table S4). Manual curating these
enriched pathways suggested that “growth/cell cycle regu-
lation” and “cellular immune response” are the major
transcriptional signature in Akt1-mediated muscle growth
(Table 1).
In the growth/cell cycle regulation category, “cyclins
and cell cycle regulation”, “estrogen-mediated S-phase
entry” and “mitotic roles of polo-like kinases” were pre-
dicted to be significantly activated pathways in the
muscle of DTG mice (p < 0.001, Z-score 3.6, 2.3 and 2,
respectively). Many transcripts encoding for cyclins,
and cyclin dependent kinases were upregulated upon
Akt1-mediated muscle growth (Fig. 6a). Consistent with
the finding that cell cycle regulation pathways are
enriched in the Akt1-mediated muscle growth, the IPA
upstream regulator analysis algorithm also identified
cyclin D1 as a nodal point regulator mediating the gene
a b
Fig. 5 Changes in amino acid metabolism associated with Akt1-mediated muscle growth. a Relative levels of essential and non-essential amino
acids (ECAA, NECAA) in the gastrocnemius muscles from DTG mice compared to those from MckrtTA mice. # denotes p-value <0.05, + denotes
p-value <0.1. b Schematic representation of changes in the expression of transcripts encoding for branch chain amino acid degradation enzymes
represented by histograms. Open column is control (MckrtTA) and filled column is DTG mice. * denotes transcripts with FDR <0.005
Wu et al. BMC Genomics  (2017) 18:181 Page 9 of 18
expression changes found in Akt1-mediated muscle
growth (Additional file 8: Figure S4A). In this analysis,
expression of 55 transcripts in Akt1-meidated muscle
growth were directly regulated by cyclin D1 as pre-
dicted by the IPA literature knowledge base (p < 0.001,
z-score 4.1, Additional file 8: Figure S4A), including
several transcription factors important for cell cycle
progression and proliferation (e.g. Myc, Foxm1, and
Uhrf1). Notably, we also observed significant increase
in the expression of Myod1 (3.7-fold) and Myog (17.6-fold)
transcripts that encode the transcriptional regulators of
early muscle differentiation in the Akt1 over-expressing
muscle (Additional file 8: Figure S4B). In addition, our
model of selective Akt1 induction in muscle is accompan-
ied by an activation of embryonic program, indicated by
the increases in transcripts encoding for isoforms associ-
ated with embryonic muscle development including car-
diac troponin T type 2 (Tnnt2) or cardiac myosin binding
protein c (Mybpc3), embryonic (Myh3) and neonatal my-
osin heavy chain (Myh8) (Additional file 8: Figure S4B).
Immunohistochemical analysis confirmed that expression
of embryonic myosin heavy chain (eMHC), encoded by
Myh3, is readily detectable in the transgenic muscle fol-
lowing 2 weeks of Akt1 overexpression (Additional file 8:
Figure S4C). Many of these eMHC-positive myofibers
contained centralized nuclei, suggestive of satellite cell re-
cruitment and the activation of a regenerative transcrip-
tional program.
Akt1-mediated muscle growth activates inflammatory
pathways
Many of the differentially expressed genes are associated
with Akt1-mediated muscle growth are modulators of
inflammation (Table 1). Six of these enriched inflamma-
tion pathways listed in Table 1 are composed of genes
that are expressed at very low levels, or below the level
of detection, in the control muscle, suggesting that their
marked upregulation during Akt1-mediated hypertrophy
may be due to the infiltration of inflammatory cells.
Several of these activated pathways share common DEGs
encoding for pro-inflammatory cytokines including Il1a,
Il1b, Il10, Ccl2 and Tnf (Fig. 6b). Other highly upregu-
lated transcripts were interleukin/chemokine receptors
(e.g. Il1r1, Il4ra, Ccr1-7), members of toll-like receptors
(e.g. Tlr1, 4, 6, 7, 8, 9) and TNF-receptor family members
(e.g. Tnfrsf11a, 1a, 1b) (Fig. 6c). The marked upregulation
of inflammatory cell markers, such as Cd68 and Itgb2, was
also observed (Fig. 6c).
As the transcriptomic data suggested that monocytic
cells infiltrate the rapidly growing muscle of DTG mice,
immunohistochemical analysis of the gastrocnemius
muscle sections was performed to assess for the pres-
ence of macrophages. The transgenic muscle mice
showed positive staining for the macrophage markers
CD68 and F4/80 (Fig. 6d). Little or no staining was de-
tected in control muscle. The CD68+ and F4/80+ cells
in the DTG mice tended to be localized to enlarged,
Table 1 Ingenuity analysis of canonical signaling pathways enriched by Akt1-mediated muscle growth
Pathways P Ratio z-score
Growth/Cell Cycle Regulation Cyclins and Cell Cycle Regulation 2.38 0.31 3.64
Integrin Signaling 4.83 0.30 2.78
ILK Signaling 4.93 0.31 2.50
Estrogen-mediated S-phase Entry 3.08 0.50 2.31
Actin Cytoskeleton Signaling 4.22 0.28 2.06
Mitotic Roles of Polo-like Kinase 3.02 0.35 2.00
p70S6K Signaling 2.39 0.28 1.77
Cellular Immune Response Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 9.02 0.46 4.42
Dendritic Cell Maturation 5.19 0.32 4.24
Leukocyte Extravasation Signaling 5.50 0.31 3.78
Toll-like Receptor Signaling 4.19 0.38 3.77
Role of Pattern Recognition Receptors in Bacteria & Viruses Recognition 4.02 0.32 3.40
Production of Nitric Oxide & Reactive Oxygen Species in Macrophages 5.52 0.32 2.94
TREM1 Signaling 6.64 0.45 2.65
IL-8 Signaling 4.23 0.29 2.50
NF-κB Signaling 4.15 0.30 2.38
Tumoricidal Function of Hepatic Natural Killer Cells 2.51 0.46 2.12
P is reported as (-log (B-H p-value)). Ratio denotes the ratio of DEG specific to the pathway in this study divided by the total number of the genes in this pathway
designated by IPA knowledge database. Z-score indicates a pathway with genes exhibition overall increased mRNA levels (positive value) or decreased mRNA
levels (negative value)
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irregular-shaped myofibers, many of which contained
centralized nuclei. These results indicate that there is an
inflammatory program in the transgenic mice that may
contribute to the activation of regenerative myogenesis
during Akt1- mediated muscle growth.
Secreted protein transcripts induced by Akt1-mediated
muscle growth
It is well established that Akt overexpression in muscle
leads to changes both in the muscle and at remote tis-
sues [15, 20–24]. To explore the hypothesis that these
changes may be coordinated by secreted proteins, can-
didate muscle-derived secreted proteins were analyzed
in the transcriptome data set. At the 2 week time point,
174 differentially regulated transcripts encoding puta-
tive secreted proteins were upregulated, whereas 66
were downregulated (Additional file 9: Table S5). A
Panther over-representation test was performed to de-
termine the protein classes represented by these differ-
entially expressed secreted proteins. This analysis
revealed that most of these encoded proteins could be
classified as chemokines, cytokines, extracellular matrix
proteins, protease or protease inhibitors (Additional file
10: Table S6). Among these putative secreted proteins,
several of the Akt1-mediated secreted proteins have been
previously characterized to mediate muscle growth/myo-
genesis (Fig. 7a), bone homeostasis (Fig. 7b), metabolism
(Fig. 7c), and cardiovascular functions (Fig. 7d). Some of
the proteins encoded by these transcripts have been
shown to be secreted into the circulation during exercise
or muscle growth, such as Igf1 [36], Fstl1 [37], Metrnl
[38], and Bdnf [39].
Discussion
A small but growing series of studies have shown that
increases in fast-twitch skeletal muscle mass, with no in-
crease in oxidative capacity, can lead to improvements
in systemic metabolism [18]. Furthermore, it is becom-
ing increasingly appreciated from clinical studies that
resistance exercise, that leads selectively to the growth of
faster-twitch muscle, can diminish the risk of cardiovas-




Fig. 6 Increased expression of cell cycle regulators and pro-inflammatory transcripts during Akt1-mediated muscle growth. Transcripts with significant
expression changes (fold change ≥ 2-fold, FDR < 0.005 for all transcripts) from RNA-seq results were represented in the histograms. a Increased
expression of transcripts encoding for cell cycle regulators in Akt1-mediated muscle growth. b Expression changes of transcripts encoding for
chemokines or cytokines in the gastrocnemius muscles of MckrtTA and DTG mice (fold change ≥ 2-fold, FDR < 0.005 for all transcripts listed).
c Increased expression of the transcripts encoding for receptors of chemokines/cytokines and inflammatory cell markers (fold change ≥ 2-fold,
FDR < 0.005 for all transcripts listed). d Immunohistochemical analysis showing the increased presence of inflammatory cell markers CD68 and
F4/80 in gastrocnemius muscle from DTG mice compared to control STG mice
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mechanisms by which fast-twitch muscle exerts these
effects are poorly understood. Some of the beneficial ef-
fects of resistance exercise on whole-body metabolism
can be attributed to the increase in calorie consump-
tion for maintaining muscle mass. In addition, the
growing muscle can secrete peptides or metabolites
into circulation that may affect remote metabolic and
cardiovascular tissues. Previously, our lab has reported
that a murine model of fast-twitch glycolytic muscle
growth that is triggered by the inducible expression of
a constitutively active Akt1 isoform. These mice display
accelerated muscle regeneration [23, 24], resistance to
systemic metabolic dysfunction [15] and preserved
function in models of cardiometabolic and renal diseases
[21, 22]. Thus, to better understand the cardiometabolic-
protective properties of Akt1-mediated muscle growth we
performed RNA sequencing and non-targeted metabolo-
mic analyses on this muscle tissue from this model.
Consistent with our previous report [15], there was a
30% increase in the mass of fast/glycolytic (gastrocnemius)
muscle from transgenic mice with 2 weeks of Akt1 over-
expression, that was accompanied by an increase in the
mean cross sectional area of type IIb myofibers and an in-
crease in the distribution of IIb myofibers. Akt1 is a multi-
functional kinase that integrates signals from nutrients,
growth factors, energy status and environment stresses to
control cellular growth. Prior studies have shown that
Akt1 is a regulator of muscle growth through activation of
mTOR signaling [17, 41]. In the current study, the
P70S6K signaling pathway, a canonical downstream sub-
strate of mTOR, was found to be enriched (Table 1), and
it is likely to contribute to Akt1-mediated muscle growth.
Combining transcriptional/metabolomic data, we
identified the robust upregulation of biosynthetic meta-
bolic pathways and the downregulation of catabolic
pathways in Akt1-mediated muscle growth. Intermedi-
ates that comprise the core metabolic pathways of gly-
colysis and the TCA cycle were depleted in the growing
muscle of the Akt1-mediated muscle growth, consistent
with a large demand for intermediates required for the
synthesis of proteins and nucleic acids. The pentose
phosphate pathway was one of the most significantly
enriched metabolic pathways in the growing muscle.
Indeed, changes in purine metabolism and increased
total RNA content in the MyoMouse muscle, suggests
Fig. 7 Akt1-mediated muscle growth alters the expression of
transcripts encoding putative secreted proteins. RNA-seq profiling
showed changes in factors implicated in the regulation of muscle
growth (a), bone homeostasis (b), whole-body metabolism (c) and
cardiovascular function (d) are shown. Open columns indicate
control (MckrtTA) mice and filled columns indicate DTG mice. For
all the transcripts listed, expression levels were changed with a
fold change ≥ 1.5-fold or ≤ -1.5-fold and FDR < 0.005
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that enhanced flux through the pentose phosphate
pathway is integral in reprograming the tissue to sup-
port rapid type IIb muscle growth. There was a signifi-
cant 2-fold increase in the level of the R5P intermediate
and increased mRNA expression of the first 2 enzymes
in the pathway, G6pdx and Pgd. G6pdx encodes for the
rate-limiting enzyme of the pathway, catalyzing the first
irreversible reaction that leads to the generation of R5P,
a precursor for de novo nucleotide biosynthesis [42].
The finding of increased flux through the pentose phos-
phate pathway upon Akt1-mediated muscle growth is
consistent with previous findings showing that G6pdx
transcriptional activation is dependent on insulin/PI3K/
Akt/mTOR signaling [43]. It has also been reported
that enzyme activities of G6pdx- and Pgd-encoded pro-
teins are significantly induced during muscle regener-
ation and that this induction can be reversed by
administration of cycloheximide and actinomycin D
[44]. Collectively, these results suggest that Akt1-medi-
ated muscle growth is dependent on enhanced pentose
phosphate pathway flux to support the rapid muscle
growth.
Akt1-mediated muscle growth led to increased leu-
cine and isoleucine accumulation, and this was accom-
panied by the diminished expression by transcripts
that encode for BCAA degradation enzymes. BCAAs,
and in particular leucine, are strong activators for
muscle protein synthesis [45, 46]. Reductions in tran-
scripts encoding BCAA catabolic enzymes have been
reported in other studies, such as muscle growth in
response to synergic ablation [47]. Notably, the signifi-
cant transcriptional suppression of BCAA degradation
enzymes in Akt-mediated muscle growth was in
marked contrast to the muscle-specific PGC1α trans-
genic mice that display a uniform increase in the tran-
scripts that encode BCAA catabolic enzymes [48]. It
was proposed that upregulation of BCAA catabolic en-
zymes (i.e. Hibch and Hibadh) in the muscle-specific
PGC1α transgenic mice results in muscle secretion of
a BCAA catabolic intermediate, 3-hydroxyisobutyrate,
which activates endothelial fatty acid transport and pro-
motes lipid accumulation in muscle, leading to insulin
insensitivity in this model [48]. In contrast, the Akt1
transgenic mice showed a 2.2-fold decrease in Hibadh
mRNA and an overall downregulated BCAA catabolism,
which provide a mechanistic explanation for the differ-
ences in insulin sensitivity observed in these two models
of high-fat diet fed transgenic mice [15].
Cyclins and cell cycle regulation are other functional
categories enriched in the DEG analysis of Akt1-medi-
ated muscle growth. Using the Upstream Regulator
Analysis in the IPA software package, Cyclin D1 was
identified as a significant regulator mediating tran-
scriptional changes in 55 genes during Akt1-mediated
muscle growth (Additional file 8: Figure S4A). These
results are consistent with the satellite cell activation
accompanied by the improvement in muscle regener-
ation previously described with this model [23]. The
finding of cell cycle activation in the Akt1-mediated
muscle growth is also consistent with a recent human
cohort study, where 16-weeks of resistance training
induced upregulation in Cyclin D1 expression, and
higher levels of satellite cell activation in the individuals
with robust muscle hypertrophy, but not in the
non-responders [49]. Increased myonuclear number
and satellite cell content occurs during muscle hyper-
trophy in humans, particularly in individuals with high
extents of muscle growth [50, 51]. Consistently, Akt1-
mediated mTOR signaling has been shown to be im-
portant for priming satellite cells for cell cycle entry
[52] and for the expression of myogenic factor such as
myogenin and MyoD (Additional file 8: Figure S4B)
[53]. In the current study, muscle growth was associate
with a 3.7-fold increase in Myod1 mRNA and a 17-fold in-
crease in myog mRNA. MyoD is known to epigenetically
regulate muscle cytoskeletal proteins expression [54] and
promote expansion of muscle progenitor cells. These
findings are consistent with a report showing that Akt1
increases myonuclei number per fiber by promoting
MyoD-mediated myogenic transcription regulation dur-
ing myoblast differentiation [55]. Finally, immune-
histochemical analysis revealed a significant increase in
embryonic-like muscle fibers during in Akt1-mediated
muscle growth (Additional file 8: Figure S4C) accom-
panied by a trend of increase in embryonic and neo-
natal myosin heavy chain (Myh3 and Myh8). Thus, we
speculate the increased expression of embryonic and
neonatal myosin heavy chain in the transgenic muscle
is a result of robust muscle progenitor cell proliferation,
followed by cell cycle arrest and differentiation.
Emerging evidence indicates that induction of fetal
sarcomeric proteins in adult tissues is triggered by or as-
sociated with the altered expression of the key metabolic
enzymes [56, 57]. In adult failing heart, for example, the
expression of fetal sarcomeric proteins is accompanied
by metabolic switching to more closely resemble the
fetal heart, such as a switch from fatty acid metabolism
to anaerobic glycolysis, which is thought to protect
against functional impairment and cell death [57]. While
it is well-established that skeletal muscle alters myofiber
type in response to stress, the consequences of metabolic
shifts during fetal re-programing is less known. In
activated satellite cells, genes regulating glycolysis are
upregulated [58, 59], and it has also been shown that
byproducts of glycolysis are required for successful
differentiation of C2C12 murine myoblasts [60]. Our
observations of reduced glycolysis in Akt1-mediated
muscle growth implies impaired myogenesis. However,
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since satellite cells account for only 3–5% of the total
number of myofiber nuclei, their contribution to the
observed changes in overall metabolite levels should be
small. On the other hand, the activation of other cell types
besides satellite cells, such as myofibroblasts, fibroblasts,
pericytes, or endothelial cells, may contribute to the en-
richment of pathways associated with cell cycle progres-
sion and the metabolic shift in the Akt1-transgenic
muscle [56, 61]. In this regard, Akt-mediated muscle
growth was associated with an activation of non-muscle
isoforms of metabolic enzymes whereas the muscle iso-
forms were downregulated in the tissue. This switch from
muscle to non-muscle isoform could reflect a metabolic
adaptation associated with the de-differentiation of the
muscle tissue. Alternatively, it could reflect greater re-
cruitment of non-muscle cell types to the tissue, such as
inflammatory cells, that predominantly express the non-
muscle isoforms.
Akt1-mediate muscle growth led to a strong signature
from inflammatory modulators in the DEG analysis.
Notably, some of the enriched inflammatory pathways
are known to be functional in skeletal muscle. For
example, enriched DEGs occurred in the “production of
nitric oxide and reactive oxygen species in macrophages”
pathway. This category included both cytosolic and
membrane bound subunits of NADPH oxidase in the
Akt1- mediated muscle growth (Nox4, gp-91 phox, p22
phox, p47 phox and p67 phox). Increased membrane
translocation of NADPH oxidase has been shown to be
one of the key sources of reactive oxygen production in
contracting muscle [62]. It has been proposed that
growth factor-mediated transient increases in H2O2 can
improve insulin sensitivity by inhibiting the action of
protein tyrosine phosphatases [63, 64], consistent with
the phenotype of the Akt1 transgenic mouse. Inflamma-
tion responses have also been associated with muscle
hypertrophy in a number of studies, and it is thought to
influence muscle regeneration by directly affecting satel-
lite cells and indirectly through the modulation of angio-
genesis and fibrosis [65, 66].
There is mounting evidence that skeletal muscle is an
endocrine tissue capable of releasing bioactive peptides or
proteins that have been referred to as “myokines” [25, 26].
In the current analysis we identified 240 differentially-
regulated transcripts encoding a putative signal peptide
and lacking of a transmembrane spanning domain. A
number of the differentially regulated transcripts encode
for proteins that have previously been shown to regulate
muscle growth, satellite activation, or myogenesis (Fig. 7a).
For example, the expression of insulin-like growth factor 1
transcript variant 2, (Igf1, uc007gqx.2, containing Class II
signal peptide and terminating at exon5) is increased by
176-fold during the Akt1-mediated muscle growth. Igf1 is
known to act both on muscle fibers and on activated
satellite cells to induce hypertrophy [67]. Notably, clinical
trials have demonstrated that recombinant human IGF-I
administration can improve insulin sensitivity in type I or
type II diabetes [68, 69]. We also found that leukemia in-
hibitory factor (Lif) transcripts are upregulated during
Akt1-mediated muscle growth. Previous studies have
shown Lif mRNA expression is modestly increased 6-h
after resistance exercise in human muscle biopsy speci-
mens and secreted into medium 3-h after electrical stimuli
of myotubes [70]. Lif has been shown to promote myo-
genic cell proliferation [70], muscle glucose uptake [71],
and is required for overload-induced muscle hypertrophy
[72]. Myostatin (Mstn), a widely studied negative regulator
of muscle growth [73], was downregulated 7.3-fold at the
transcription level in Akt1-mediated muscle growth.
These findings are consistent with a study showing that
Mstn mRNA is downregulated by resistance exercise in
human muscle [74].
It was of interest to assess whether the Akt1 trans-
genic model was capable of regulating transcripts in
muscle that could potentially be involved in bone
homeostasis. The analysis also identified several regu-
lated transcripts encoding for proteins implicated in
bone growth and protection (Fig. 7b). Collagen triple
helix repeat containing 1 (Cthrc1) transcript increased
84-fold in Akt1-mediated muscle growth. Cthrc1 en-
codes for a secreted protein that was first identified to
increase bone mass by regulating osteoblast prolifera-
tion and differentiation [75]. Recent studies also show
that this factor has a metabolic function, as whole-body
Cthrc1 deficiency will promote liver steatosis and in-
creased subcutaneous fat mass [76, 77]. Another example
is biglycan (encoded by Bgn) that is induced 11-fold by
Akt1 in muscle. Biglycan is a member of small leucine-
rich proteoglycan family that is abundantly expressed in
mineralized tissues. Whole-body Bgn-deficient mice dis-
play defective bone formation and mineralization [78],
and biglycan has been shown to promote proper blood
vessel formation during fracture repair [79] and regulate
muscle-tendon formation during development [80]. It has
also been shown that biglycan impedes progression of ath-
erosclerosis by mitigating thrombin activities and inflam-
mation, suggesting that this factor can have other systemic
actions [81].
Akt1-mediated muscle growth leads to the increased
expression of several transcripts encoding metabolic-
regulatory proteins (Fig 7c). Among these, the transcript
encoding Fgf21 was robustly upregulated (250-fold), con-
sistent with a previous report [82]. Fgf21 functions as a
metabolic regulator capable of lowering blood glucose in
animals with diabetes, although this effect was not
observed in clinical trials [83]. It has also been shown that
Fgf21 induction decreases plasma triglycerides in rodent
and human [84, 85], and that it has cardio-protective
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actions in mice [86]. It has been reported that serum
FGF21 level increased 1 hour after a moderate to high in-
tense treadmill exercise [87], but several reports suggested
that liver instead of the skeletal muscle is the main en-
dogenous source after exercise. In addition, Meteorin-like
protein (Metrnl) was upregulated during Akt1-induced
muscle growth. Meteorin-like protein was shown to be in-
duced in muscle by the overexpression of PGC1-α4 [38].
This factor can be induced in human muscle after a bout
of combined resistance and endurance exercise, and it is
secreted into circulation in mice after an acute bout of
downhill running exercise. In addition, several myokines
identified from the transcriptome data in Akt1-mediated
muscle growth have been previously shown to regulate en-
ergy homeostasis by controlling patterns of feeding and
neural circuits. For example, Bdnf, a member of the neu-
rotrophin family, increased 153-fold at the mRNA level in
the Akt1-mediated muscle growth. Both human and
mouse data showed that decreased brain-derived neuro-
trophic factor (BDNF) is associated with the hyperphagia,
development of obesity and neurodegenerative disease
[88, 89]. BDNF and its cognate receptor TrkB have been
implicated to regulate food intake and appetite by tar-
geting at ventromedial nuclei in the hypothalamus and
dorsal vagal complex in the brainstem [89, 90].
Multiple tissues and cell types express BDNF [90]. In
skeletal muscle, BDNF overexpression increases fatty
acid oxidation in an AMPK-dependent manner and cir-
culating BDNF is increased after exercise [39]. Fndc5,
the transcript that encodes the putative irisin precursor
protein, decreased 2-fold in transcript level in the
Akt1-mediated muscle growth. Although controversial,
modest increases in circulating irisin levels were ob-
served after exercise training in both mouse and human
[91], and it is reported to improve cognitive function
by inducing BDNF and other neuroprotective genes in
hippocampus [92].
Akt1-mediated muscle growth also led to the induc-
tion of several factors that are known to regulate car-
diovascular function (Fig. 7d). Several of these have
been shown to be protective in models of myocardial
ischemia-reperfusion injury including Il1rn, Fstl1,
Isg15, Plat, Ncub2 and Sod3. Notably, the transcript en-
coding for follistatin-like 1 (Fstl1) increased by 5.7-fold
during Akt1-mediated muscle growth. FSTL1 is upregu-
lated in skeletal muscle by strength-training in individuals
[93], and increased circulating FSTL1 was found after
60 min of cycling exercise [37]. Numerous studies have
shown that Fstl1 has cardiorenal-protective properties
[94]. Plat mRNA was increased 3.5-fold in the transgenic
muscle. Plat encodes tissue-type plasminogen activator
(t-PA), which converts the zymogen plasminogen into
proteolytically active serine protease plasminogen that
degrades fibrin clots and has been shown to be an
effective acute treatment in acute myocardial infarction
[95]. Elevated circulating t-PA has been shown after both
acute endurance and resistance exercises in human [96].
Although endothelium is the main site of t-PA production,
t-PA is present at low levels in normal mouse muscles and
it is induced during muscle regeneration [97]. This tran-
scriptomic analysis of muscle-specific Akt1 transgenic
mice identified a number of putative myokines that are
regulated during fast-twitch/glycolytic muscle growth.
While several of these myokine candidates have been
studied previously, the majority of these proteins have yet
been characterized in the context of muscle growth or
cardio-metabolic regulation.
Conclusion
In summary, we have utilized an inducible, muscle-
specific Akt1-transgenic mouse system to characterize
metabolic and gene expression profiles associated with
fast-twitch muscle growth. These results revealed that
muscle growth was accompanied by reduced glycolysis
and oxidative phosphorylation, and the activation of
pathways that favor the biosynthesis of macromole-
cules. Previous work with this model of muscle growth
have documented enhanced sarcolemma stability dur-
ing muscle degeneration, improved whole-body metab-
olism in diet-induced obesity, and tissue protection in
models of heart failure and kidney injury. Unbiased
profiling identified numerous transcripts encoding se-
creted proteins that may confer some of the systemic
protective actions of fast-twitch skeletal muscle.
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